felodipine has been researched along with isradipine in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (54.17) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 5 (20.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dietel, M; Höllt, V; Kouba, M; Vogt, G | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Sun, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bladen, C; Dunn, SM | 1 |
| Cross, AJ; Green, AR; Little, HJ; Misra, A; Watson, WP | 1 |
| Cutler, SA; Hammond, JJ | 2 |
| Symes, LR; Walton, T | 1 |
| Ickrath, O; Karsch, KR; Mauser, M; Voelker, W | 1 |
| Block, LH; Nauck, M; Rödler, S; Roth, M; Tamm, M | 1 |
| Bailey, CP; Little, HJ; Molleman, A | 1 |
| Mészáros, LG; Minarovic, I | 1 |
| Rodríguez Moreno, C | 1 |
| Seibold, JR; Sturgill, MG | 1 |
| Akkaya, V; Ark, E; Ecder, T; Sever, MS; Türk, S; Türkmen, A; Yildiz, A | 1 |
| Sahney, S | 1 |
3 review(s) available for felodipine and isradipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.
Topics: Angina Pectoris; Animals; Drug Interactions; Felodipine; Heart Failure; Hemodynamics; Humans; Hypertension; Isradipine; Kidney | 1993 |
A review of calcium channel antagonists in the treatment of pediatric hypertension.
Topics: Amiodarone; Calcium Channel Blockers; Child; Felodipine; Humans; Hypertension; Isradipine; Nicardipine; Nifedipine; Verapamil | 2006 |
4 trial(s) available for felodipine and isradipine
| Article | Year |
|---|---|
A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician's Study Group.
Topics: Adolescent; Adult; Aged; Ankle; Blood Pressure; Double-Blind Method; Drug Tolerance; Edema; Enalapril; Felodipine; Female; Heart Rate; Humans; Hypertension; Isradipine; Lipids; Male; Middle Aged | 1993 |
A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group.
Topics: Adult; Ankle; Double-Blind Method; Drug Therapy, Combination; Edema; Enalapril; Felodipine; Female; Headache; Humans; Hypertension; Isradipine; Male; Middle Aged; Treatment Outcome | 1993 |
[Comparison of the cardiodepressive effects of nifedipine, isradipine, nisoldipine and felodipine in patients with coronary heart disease].
Topics: Adult; Aged; Calcium Channel Blockers; Coronary Disease; Electrocardiography; Exercise Test; Felodipine; Female; Hemodynamics; Humans; Infusions, Intravenous; Isradipine; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Nifedipine; Nisoldipine | 1993 |
Interaction between cyclosporine A and verapamil, felodipine, and isradipine.
Topics: Adult; Calcium Channel Blockers; Cyclosporine; Drug Interactions; Felodipine; Female; Humans; Immunosuppressive Agents; Isradipine; Kidney Transplantation; Male; Verapamil | 1999 |
17 other study(ies) available for felodipine and isradipine
| Article | Year |
|---|---|
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Biological Transport; Calcium Channel Blockers; Cell Line; Dihydropyridines; Drug Resistance; Haplorhini; Immunoblotting; Membrane Glycoproteins; Mice; RNA, Messenger; Stereoisomerism; Verapamil; Vinblastine | 1992 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
Topics: Carboxylic Acids; Cytochrome P-450 Enzyme System; Esters; Humans; Hydrolysis; Microsomes; Models, Molecular; Molecular Structure; Prodrugs; Quantum Theory; Signal Transduction | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Low-affinity binding sites for 1,4-dihydropyridines in skeletal muscle transverse tubule membranes revealed by changes in the fluorescence of felodipine.
Topics: Animals; Binding Sites; Binding, Competitive; Calcium Channel Blockers; Cations; Cell Membrane; Dihydropyridines; Felodipine; Fluorescent Dyes; Isradipine; Kinetics; Muscles; Rabbits; Spectrometry, Fluorescence | 1992 |
The differential effects of felodipine and nitrendipine on cerebral dihydropyridine binding ex vivo and the ethanol withdrawal syndrome in mice.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Bicuculline; Binding Sites; Brain; Ethanol; Felodipine; Isradipine; Male; Mice; Nitrendipine; Substance Withdrawal Syndrome | 1994 |
Ca(2+)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells.
Topics: Adrenergic beta-Antagonists; Amlodipine; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Cells, Cultured; Dihydropyridines; Diuretics; Felodipine; Fibroblasts; Furosemide; Gene Expression Regulation; Humans; Interleukin-6; Interleukin-8; Isradipine; Lung; Muscle Proteins; Muscle, Smooth, Vascular; Nitrobenzenes; Piperazines; Propranolol; Transcription, Genetic | 1995 |
Comparison of the effects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption.
Topics: Acetates; Alcoholism; Amines; Animals; Behavior, Animal; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diltiazem; Ethanol; Felodipine; Gabapentin; gamma-Aminobutyric Acid; Hippocampus; Isradipine; Male; Membrane Potentials; Mice; Mice, Inbred C57BL; Substance Withdrawal Syndrome | 1998 |
Fluorescent probing with felodipine of the dihydropyridine receptor and its interaction with the ryanodine receptor calcium release channel.
Topics: Animals; Binding Sites; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Diltiazem; Dogs; Felodipine; Fluorescent Dyes; In Vitro Techniques; Isradipine; Kinetics; Muscle, Skeletal; Myocardium; Protein Conformation; Rabbits; Ryanodine; Ryanodine Receptor Calcium Release Channel; Sarcolemma; Sarcoplasmic Reticulum; Spectrometry, Fluorescence | 1998 |
[Calcium antagonists and their impact on coronary risk].
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Felodipine; Humans; Hypertension; Isradipine; Risk Factors; Vasodilator Agents | 1998 |
Rational use of calcium-channel antagonists in Raynaud's phenomenon.
Topics: Amlodipine; Calcium Channel Blockers; Diltiazem; Felodipine; Humans; Isradipine; Nicardipine; Nifedipine; Raynaud Disease | 1998 |